Ownership Summary
According to SEC filings for the period ending September 2025, Lyell Immunopharma, Inc. (NASDAQ:LYEL) is held by 2 institutional firms.
- Lyell Immunopharma saw its institutional ownership percentage fell to 4.6% in September 2025 from 17.9% in June 2025.
- Quarterly data indicates a 2.16% shift in institutional share volume, and the annual owner count reflects a decrease of 98.29%.
- During the quarter, 1 institutions bought more Lyell Immunopharma shares, 0 sold shares, and 1 of the 2 total investors held their position steady.
- Collectively, institutional investors increased their stake in Lyell Immunopharma to 650.35K shares as of September 2025, a change that is up by 13.72K shares quarter on quarter and down 5.76Mn shares year over year.
- As of September 30, 2025, Decheng Capital LLC held Lyell Immunopharma's largest shareholding position with over 595.47K shares, representing 4.21% of total outstanding shares.
- Among the most significant buyers of Lyell Immunopharma during September 2025 were TAKEDA PHARMACEUTICAL CO LTD (13.72K).
- The top 2 institutional holders of Lyell Immunopharma for the quarter ending September 2025 included Decheng Capital LLC (595.47K), TAKEDA PHARMACEUTICAL CO LTD (54.89K).